tbuckley/cabot-search huggingface dataset:
Worldwide Variations in Demographics, Management, and Outcomes of Acute Pancreatitis
Authors: Bassem Matta, Amir Gougol, Xiaotian Gao, Nageshwar Reddy, Rupjyoti Talukdar, Rakesh Kochhar, Mahesh Kumar Goenka, Aiste Gulla, Jose A. Gonzalez, Vikesh K. Singh, Miguel Ferreira, Tyler Stevens, Sorin T. Barbu, Haq Nawaz, Silvia C. Gutierrez, Narcis O. Zarnescu, Gabriele Capurso, Jeffrey Easler, Konstantinos Triantafyllou, Mario Pelaez-Luna, Shyam Thakkar, Carlos Ocampo, Enrique de-Madaria, Gregory A. Cote, Bechien U. Wu, Pedram Paragomi, Ioannis Pothoulakis, Gong Tang, Georgios I. Papachristou
Journal: Clinical Gastroenterology and Hepatology (2019)
Predictive Factors for Thrombopoietin Receptor Agonist Free Responses in Chronic ITP Patients: A Multicenter Retrospective Study with Long-Term Follow-up
Authors: Maria Luisa Lozano, Maria Eva Mingot-Castellano, María Perera, Isidro Jarque, Rosa Maria Campos, Tomás José González-López, Gonzalo Carreño Gomez-Tarragona, Nuria Bermejo, Maria Fernanda Lopez Fernandez, Aurora de Andrés, David Valcarcel, Felipe Casado, Teresa Álvarez Roman, María Isabel Orts, Silvana Novelli, Nuria Revilla, Jose Ramon González-Porras, Estefanía Bolaños, Manuel Rodríguez López, Elisa Orna, Vicente Vicente Garcia
Journal: Blood (2019)
VEGF-A drives TOX-dependent T cell exhaustion in anti–PD-1–resistant microsatellite stable colorectal cancers
Authors: Chang Gon Kim, Mi Jang, Youngun Kim, Galam Leem, Kyung Hwan Kim, Hoyoung Lee, Tae-Shin Kim, Seong Jin Choi, Hyung-Don Kim, Ji Won Han, Minsuk Kwon, Jong Hoon Kim, Andrew J. Lee, Su Kyung Nam, Seok-Joo Bae, Sat Byol Lee, Sang Joon Shin, Sung Ho Park, Joong Bae Ahn, Inkyung Jung, Kang Young Lee, Su-Hyung Park, Hoguen Kim, Byung Soh Min, Eui-Cheol Shin
Journal: Science Immunology (2019)

VEGF-A drives T cell exhaustion via TOX-dependent transcriptional programming in microsatellite stable colorectal cancers.
Humanized CD19 CAR-T Cell Combined with Multiple Combination Treatments in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Authors: Jia Wang, Ji-jun Yuan, Juan Mu, Qing Li, Nan Mou, Zhen-xing Yang, Wei Li, Lanfang Li, Peiqi Zhao, Xianhuo Wang, Yedi Pu, Huilai Zhang, Qi Deng
Journal: Blood (2019)
NIMG-18. EFFECT OF BEVACIZUMAB AGAINST CYSTIC PART OF BRAIN TUMOR
Authors: Fumiyuki Yamasaki, Motoki Takano, Ushio Yonezawa, Akira Taguchi, Shumpei Onishi, Kazuhiko Sugiyama, Kaoru Kurisu
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Bevacizumab improves the symptom via reducing the peritumoral edema and/or normalizing BBB, and occasionally via reducing the tumor size. However, the effect against active cystic portion has not been documented yet. We focused on the effect of bevacizumab on cystic component of brain tumors. MATERIALS AND METHODS Between 2008 and 2018, 139 patients with primary or metastatic brain tumor were treated with bevacizumab in our institution. We defined cystic lesions as high intense lesion of size ≥1 cm on T2-weighted imaging, and excluded necrotizing cysts and cystic changes in surgical resection cavity. The images before and after administration of bevacizumab were examined, and changes in cyst size was evaluated as follows: CR, PR, MR (reduction by ≥25%), SD, PD. The effect of bevacizumab on tumor itself was determined according to RANO criteria. RESULTS Of the 139 patients, 212 (15.1%) had cystic component. Among these 21 tumors, 14 had progressively increasing cysts prior to bevacizumab administration. On the first imaging following administration of bevacizumab, the response of cysts were as follows: CR 2, PR 7, MR 7, SD 5. The best response of cyst to bevacizumab treatment were as follows: CR 6, PR 7, MR 4, SD 4. The group of patients with progressively increasing cysts prior to bevacizumab treatment had significant cyst size reduction compared to stable cyst size groups, at initial image after bevacizumab (mean 62.6% vs. 22.5%, P=0.0055) and at best response timing (mean 76.3% vs. 32.8%, P=0.0050). The effect on the tumor itself was not associated with cyst responses, and the response rate as per RANO was as follows: CR 1, PR 11, SD 9. CONCLUSION Bevacizumab is effective against progressively increasing cysts. Although cyst reduction effect and tumor response are independent, bevacizumab may be effective for patients who are symptomatic due to cystic enlargement.
Care of the Transgender Patient
Authors: Wendy Klein
Journal: Annals of Internal Medicine (2019)

Letters19 November 2019Care of the Transgender PatientWendy Klein, MDWendy Klein, MDHealth Brigade, Richmond, Virginia (W.K.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L19-0533 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:As a provider of care to transgender patients, I read Safer and Tangpricha's (1) article with appreciation and interest. I have provided menopausal hormones for many years before becoming a provider to transgender patients and have been a member of the North American Menopause Society since its inception. As such, I have always followed this organization's evidence-based position statements and treatment guidelines through the years. To my knowledge, the North American Menopause Society has never endorsed injectable estradiol because of the lack of safety data and variable pharmacokinetics, including unequable bioavailability and a notable peak and trough ...Reference1. Safer JD, Tangpricha V. Care of the transgender patient. Ann Intern Med. 2019;171:ITC1-16. [PMID: 31261405]. doi:10.7326/AITC201907020 LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Health Brigade, Richmond, Virginia (W.K.)Disclosures: The author has disclosed no conflicts of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L19-0533. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoCare of the Transgender Patient Joshua D. Safer and Vin Tangpricha Care of the Transgender Patient Ellen D. Herbst , Edith Harris , David L. Pennington , and Steven L. Batki Care of the Transgender Patient Joshua D. Safer and Vin Tangpricha Metrics 19 November 2019Volume 171, Issue 10Page: 774-775KeywordsConflicts of interestDisclosureEstradiolEvidence based medicineHormonesMenopausePatientsPharmacokineticsSafetyTreatment guidelines ePublished: 19 November 2019 Issue Published: 19 November 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
The Impact of Aminoacid Substitution at Position 116 Class I HLA, in Unrelated Donor Transplants
Authors: Patrizia Chiusolo, Teresa Lamparelli, Giuseppe Sapienza, Alida Dominietto, Anna Maria Raiola, Carmen Di Grazia, Sabrina Giammarco, Francesca Gualandi, Elisabetta Metafuni, Monica Rossi, Gessica Minnella, Simona Sica, Andrea Bacigalupo, Emanuele Angelucci
Journal: Blood (2019)
Haematemesis and Melaena
Authors: C. D. Needham, J. A. McConachie
Journal: BMJ (1950)

discipline will induce the patient to take the necessary precautions to prevent another abortion from occurring.(3) That each of the "successfully" treated pregnancies proceeded beyond the 28th week by chance.The second possibility seems to us unlikely.The last suggestion has been fully considered above.As to the first possibility, our results would indicate that progesterone is the essential hormonal factor for maintaining pregnancy, and that adequate progesterone therapy should not be dis- counted as a method of preventing the recurrent factor in abortion sequences.The results certainly do not conform with Hamblen's (1939) warning that exogenous progesterone may hinder the intrinsic metabolism of progesterone, nor do they support the contention (Hoffman, 1944) that pro- gesterone therapy should be employed only in cases in which the pregnanediol level has been shown to be sub- normal.SummaryA series of 45 cases of habitual abortion treated prophy- lactically with progesterone pellet implantation (six 25-mg.pellets) yielded successful results in 86% of the patients with a history of two previous abortions, 89% with three previous abortions, and 75% with four or more previous abortions.The series was subdivided into " primary " habitual abortion (in which all previous pregnancies had resulted in abortion) and secondary" habitual abortion (in which one or more previous pregnancies, but not those immediately preceding the treated pregnancy, had proceeded beyond the 28th week).In these groups the results for primary habitual abortion were: 90% success with two previous abortions, 88% success with three previous abortions, and 60% success with four or more previous abortions; and for secondary habitual abortion, 75% success for two consecutive abortions immediately preceding the treated pregnancy and uniform success for the four cases of three or more abortions.If the true incidence of "recurring" abortion is not much less than 0.1% these results indicate that the treatment was of value.Statistical Methods Used.-The probabilities of obtaining the observed number of successes and failures in each group have been calculated direct from the binomial theorem, using the three different sets of estimates of the expected success rates.The combined probabilities for each set of three groups have been calculated from the formula: X= -2 logep.Our thanks are due to Professor A. Bradford Hill and Mr. P. Armitage for their interest and advice concerning the statistical methods used, and to members of the staff of the Chelsea Hospital for Women, who have referred many of the cases in this series to us for implantation.
TBC1D8B Mutations Implicate RAB11-Dependent Vesicular Trafficking in the Pathogenesis of Nephrotic Syndrome
Authors: Lina L. Kampf, Ronen Schneider, Lea Gerstner, Roland Thünauer, Mengmeng Chen, Martin Helmstädter, Ali Amar, Ana C. Onuchic-Whitford, Reyner Loza Munarriz, Afig Berdeli, Dominik Müller, Eva Schrezenmeier, Klemens Budde, Shrikant Mane, Kristen M. Laricchia, Heidi L. Rehm, Daniel G. MacArthur, Richard P. Lifton, Gerd Walz, Winfried Römer, Carsten Bergmann, Friedhelm Hildebrandt, Tobias Hermle
Journal: Journal of the American Society of Nephrology (2019)

Mutations in about 50 genes have been identified as monogenic causes of nephrotic syndrome, a frequent cause of CKD. These genes delineated the pathogenetic pathways and rendered significant insight into podocyte biology.We used whole-exome sequencing to identify novel monogenic causes of steroid-resistant nephrotic syndrome (SRNS). We analyzed the functional significance of an SRNS-associated gene in vitro and in podocyte-like Drosophila nephrocytes.We identified hemizygous missense mutations in the gene TBC1D8B in five families with nephrotic syndrome. Coimmunoprecipitation assays indicated interactions between TBC1D8B and active forms of RAB11. Silencing TBC1D8B in HEK293T cells increased basal autophagy and exocytosis, two cellular functions that are independently regulated by RAB11. This suggests that TBC1D8B plays a regulatory role by inhibiting endogenous RAB11. Coimmunoprecipitation assays showed TBC1D8B also interacts with the slit diaphragm protein nephrin, and colocalizes with it in immortalized cell lines. Overexpressed murine Tbc1d8b with patient-derived mutations had lower affinity for endogenous RAB11 and nephrin compared with wild-type Tbc1d8b protein. Knockdown of Tbc1d8b in Drosophila impaired function of the podocyte-like nephrocytes, and caused mistrafficking of Sns, the Drosophila ortholog of nephrin. Expression of Rab11 RNAi in nephrocytes entailed defective delivery of slit diaphragm protein to the membrane, whereas RAB11 overexpression revealed a partial phenotypic overlap to Tbc1d8b loss of function.Novel mutations in TBC1D8B are monogenic causes of SRNS. This gene inhibits RAB11. Our findings suggest that RAB11-dependent vesicular nephrin trafficking plays a role in the pathogenesis of nephrotic syndrome.
Ibrutinib Maintenance after Chemoimmunotherapy Is Feasible and Results in Excellent Progression-Free and Overall Survival in Patients with Detectable MRD after Chemoimmunotherapy
Authors: Nayara Ribeiro Guedes, Ana Rita Da Fonseca, Thiago Xavier Carneiro, Vinicius Campos de Molla, Rodrigo Santucci Silva, Sérgio Costa Fortier, Vera Lucia de Piratininga Figueiredo, Larissa Ommati, Valeria Buccheri, Gislaine Borba Oliveira, Leila Martins Perobelli, Fernando Sergio Blumm Ferreira, Matheus Vescovi, Celso Arrais-Rodrigues
Journal: Blood (2019)
Clinically Suspected Cast Nephropathy: A Retrospective, Multi-Center, Real-World Study
Authors: Agoston Gyula Szabo, Jonathan Thorsen, Charlotte Toftmann Hansen, Maja Ølholm Vase, Manuela Teodorescu, Simon Bo Pedersen, Simon Bertram Flæng, Ulf Christian Frølund, Annette Juul Vangsted, Torben Plesner
Journal: Blood (2019)
Acid Drinks and Sulphonamide Therapy
Authors: P. Potter
Journal: BMJ (1947)

adrenalitie reaction as the first.Thus it has been established that, although the adrenaline content of the blood in the first cat was stil abnormally high, after an initial rise of pressure it did not further affect the blood pressure level.But after severing the nerves from the blood vessels of the ear, the adrenaline effect lasted for hours.It is quite clear that the vasoconstrictors and vasodilators counteract any factor which tends to produce abnormal pressure.The level of pressure is conditioned by the requirements of the body and not by abnormal substances in the blood such as adrenaline or renin, which tend to raise the pressure.This is the reason why it is so very difficult either to raise or to lower arterial pressure for any length of time.-Iam, etc., Liverpool.I.
Haemoglobin concentration and linear cardiac output, peripheral resistance, and oxygen transport
Authors: V Loughlin, R Lalsingh, J Maginness
Journal: BMJ (1986)

haemoglobin concentration for maximising total oxygen transport should also be 80-120 g/l, and it is this notion that concers us.In our group of 40 patients with a mean haemoglobin concentration of 106 g/l the regression of oxyg transpo on haemoglobin was similarly positive at high and low
Detection of Bladder Cancer Using a Proteomic Assay
Authors: Donald B Louria
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TP53 Expression Correlates with TP53 Mutations and Is an Independent Predictor of Clinical Outcome in Patients with DLBCL Treated with R-CHOP
Authors: Pedro Farinha, Daisuke Ennishi, Anja Mottok, Susana Ben-Neriah, Barbara Meissner, Merrill Boyle, Jeffrey W. Craig, Graham W Slack, Diego Villa, Kerry J Savage, Laurie H Sehn, Ryan D. Morin, Marco A. Marra, Joseph M. Connors, Randy D. Gascoyne, Christian Steidl, David W. Scott
Journal: Blood (2019)
ICON 2019—International Scientific Tendinopathy Symposium Consensus: There are nine core health-related domains for tendinopathy (CORE DOMAINS): Delphi study of healthcare professionals and patients
Authors: Bill Vicenzino, Robert-Jan de Vos, Hakan Alfredson, Roald Bahr, Jill L Cook, Brooke K Coombes, Siu Ngor Fu, Karin Gravare Silbernagel, Alison Grimaldi, Jeremy S Lewis, Nicola Maffulli, SP Magnusson, Peter Malliaras, Sean Mc Auliffe, Edwin H G Oei, Craig Purdam, Jonathan D Rees, Ebonie Kendra Rio, Alex Scott, Cathy Speed, Inge van den Akker-Scheek, Adam Weir, Jennifer Moriatis Wolf, Johannes Zwerver
Journal: British Journal of Sports Medicine (2019)

Background The absence of any agreed-upon tendon health-related domains hampers advances in clinical tendinopathy research. This void means that researchers report a very wide range of outcome measures inconsistently. As a result, substantial synthesis/meta-analysis of tendon research findings is almost futile despite researchers publishing busily. We aimed to determine options for, and then define, core health-related domains for tendinopathy. Methods We conducted a Delphi study of healthcare professionals (HCP) and patients in a three-stage process. In stage 1, we extracted candidate domains from clinical trial reports and developed an online survey. Survey items took the form: ‘The ‘ candidate domain’ is important enough to be included as a core health-related domain of tendinopathy’; response options were: agree, disagree, or unsure. In stage 2, we administered the online survey and reported the findings. Stage 3 consisted of discussions of the findings of the survey at the ICON (International Scientific Tendinopathy Symposium Consensus) meeting. We set 70% participant agreement as the level required for a domain to be considered ‘core’; similarly, 70% agreement was required for a domain to be relegated to ‘not core’ (see Results next). Results Twenty-eight HCP (92% of whom had &gt;10 years of tendinopathy experience, 71% consulted &gt;10 cases per month) and 32 patients completed the online survey. Fifteen HCP and two patients attended the consensus meeting. Of an original set of 24 candidate domains, the ICON group deemed nine domains to be core. These were: (1) patient rating of condition, (2) participation in life activities (day to day, work, sport), (3) pain on activity/loading, (4) function, (5) psychological factors, (6) physical function capacity, (7) disability, (8) quality of life and (9) pain over a specified time. Two of these (2, 6) were an amalgamation of five candidate domains. We agreed that seven other candidate domains were not core domains: range of motion, pain on clinician applied test, clinical examination, palpation, drop out, sensory modality pain and pain without other specification. We were undecided on the other five candidate domains of physical activity, structure, medication use, adverse effects and economic impact. Conclusion Nine core domains for tendon research should guide reporting of outcomes in clinical trials. Further research should determine the best outcome measures for each specific tendinopathy (ie, core outcome sets).
QOLP-23. IDENTIFICATION OF CHARACTERISTICS THAT DETERMINE BEHAVIORAL AND PERSONALITY CHANGES IN GLIOMA PATIENTS
Authors: Hanneke Zwinkels, Linda Dirven, Helen Bulbeck, Robin Grant, Ingela Oberg, Johan Koekkoek, Esther Habets, Kathy Oliver, Andrea Pace, Alley Rooney, Martin Taphoorn
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Glioma patients may experience behavioral and personality changes (BPC), which have a negative impact on the lives of both brain tumor patients and their relatives. The extent of BPC is currently unknown, and it is unclear if available assessment tools cover all aspects of BPC that are relevant for glioma patients. This study aimed to determine which characteristics of BPC are relevant for glioma patients. METHODS Possible characteristics of BPC were identified in the literature and based on expert opinion. Next, these 49 items were presented to patients and caregivers/former caregivers in an online survey launched via the International Brain Tumour Alliance. Participants were requested to indicate the relevance for each characteristic on a 4-point Likert scale ranging from ‘not at all’ to ‘very much’. In addition, they had to indicate which three characteristics had most impact on their daily life, and if characteristics were missing. RESULTS Completed surveys were obtained from 141 respondents, of which 36% were patients, 50% caregivers and 14% unknown. Most patients had grade II or IV glioma (29% vs 38%). Of 49 characteristics, 35 were reported as relevant in at least 25% (range all characteristics: 7–44%). Patients (n=50) and caregivers (n=70) rated different characteristics as most important. Common characteristics were lack of motivation, change in being socially active, not able to finish things and change in level of irritation. There were no characteristics reported to be missing by ≥5 respondents. CONCLUSION The majority of characteristics were rated as relevant in &gt;25% of respondents, and patients and caregivers differed in which were most relevant. A clear definition based on these results is therefore difficult to establish. A next step would be to perform a cluster analysis of patients and caregivers separately, and discuss the results with experts, to reach consensus on an appropriate definition.
Clonal Evolution of Multiple Myeloma in Patients from Diagnosis to First Relapse, Who Were Treated in Subsequent Clinical Trials
Authors: Mark van Duin, Annemiek Broijl, Jasper Koenders, Sonja Zweegman, Monique C. Minnema, Francois G. Kavelaars, Remco Hoogenboezem, Kazem Nasserinejad, Mario Boccadoro, Peter Valk, Pieter Sonneveld
Journal: Blood (2019)
ACTR-27. EVOLUTION OF THE NEUROSURGEON’S ROLE IN CLINICAL TRIALS FOR GBM: A SYSTEMATIC OVERVIEW OF THE CLINICALTRIALS.GOV DATABASE
Authors: Alireza Mansouri, Michelle Beyn, Aditya Pancholi, Clement Chow, Alexandre Boutet, Gavin Elias, Jurgen Germann, Gelareh Zadeh
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND The therapeutic challenge of glioblastoma (GBM) has catalyzed the active pursuit of a high volume of clinical trials to evaluate novel interventions for this deadly disease. Our enhanced understanding of the biology of GBMs has translated into an evolution of the role of the neurosurgeon as well. In this study, we have evaluated the current landscape of surgical clinical trials in GBM to characterize this evolution, describe current trends, and identify potential gaps in methodological features. METHODS The ClinicalTrials.gov database was searched for surgical/procedural trials in individuals with GBM on May 14th, 2019 without date limitations. Demographics, specific intervention (e.g. technical, device use, or local drug delivery), phase, sample size, and main outcome measures were abstracted. RESULTS 270 of 2140 trials (12.6%) were identified as procedural. The majority were based in the USA (189/270, 70%), single-center (188/270, 70%), and not randomized by design (215/270, 80%). Primary and recurrent GBMs were evenly addressed. Industry-funding supported 106/270 (39%) of studies. The leading test intervention was local delivery of therapeutics (44.8%), followed by use of novel devices (33%). Surgical technique/procedures comprised 20%. Early Phase designs predominated (177/270, 65.5%) but 67 (24.8%) did not report Phase. The greatest surge in new registrations over the last decade was seen in Phase I trials. The top primary outcome was safety/tolerability/ feasibility (107/270, 39%), followed by survival (62/270, 22%); 35 (12.6%) did not report a primary outcome. Approximately 15% of studies were terminated, withdrawn or suspended. Only 6 records were associated with reported results. CONCLUSIONS In GBMs, procedural interventions comprise a notable proportion of trials. Local delivery of therapeutics and novel device applications, predominantly through Phase I designs, represent the evolved role of the neurosurgeon in neuro-oncology. Improved documentation of design, outcomes, and reporting of results are needed to better inform the field and increase efficiency.